$5.4
Black Diamond Therapeutics is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 54 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Black Diamond Therapeutics stock
How to buy Black Diamond Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BDTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Black Diamond Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Black Diamond Therapeutics stock price (NASDAQ: BDTX)
Use our graph to track the performance of BDTX stocks over time.Black Diamond Therapeutics shares at a glance
Latest market close | $5.40 |
---|---|
52-week range | $1.62 - $7.66 |
50-day moving average | $5.47 |
200-day moving average | $4.55 |
Wall St. target price | $13.83 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.50 |
Is it a good time to buy Black Diamond Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Black Diamond Therapeutics price performance over time
Historical closes compared with the close of $5.4 from 2024-09-06
1 week (2024-08-30) | -11.48% |
---|---|
1 month (2024-08-07) | 18.42% |
3 months (2024-06-07) | 4.05% |
6 months (2024-03-07) | 28.57% |
1 year (2023-09-07) | 53.85% |
---|---|
2 years (2022-09-07) | 84.30% |
3 years (2021-09-07) | 9.97 |
5 years (2019-09-03) | N/A |
Black Diamond Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -40.41% |
Return on equity TTM | -83.38% |
Profit margin | 0% |
Book value | $1.97 |
Market Capitalization | $344.7 million |
TTM: trailing 12 months
Black Diamond Therapeutics share dividends
We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.
Black Diamond Therapeutics share price volatility
Over the last 12 months, Black Diamond Therapeutics's shares have ranged in value from as little as $1.62 up to $7.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Black Diamond Therapeutics's is 2.492. This would suggest that Black Diamond Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Black Diamond Therapeutics overview
Black Diamond Therapeutics, Inc. , a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc.
Frequently asked questions
nullWhat percentage of Black Diamond Therapeutics is owned by insiders or institutions?
Currently 2.327% of Black Diamond Therapeutics shares are held by insiders and 95.226% by institutions. How many people work for Black Diamond Therapeutics?
Latest data suggests 54 work at Black Diamond Therapeutics. When does the fiscal year end for Black Diamond Therapeutics?
Black Diamond Therapeutics's fiscal year ends in December. Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics's address is: One Main Street, Cambridge, MA, United States, 02142 What is Black Diamond Therapeutics's ISIN number?
Black Diamond Therapeutics's international securities identification number is: US09203E1055 What is Black Diamond Therapeutics's CUSIP number?
Black Diamond Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09203E105
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question